WebMay 28, 2024 · Capecitabine is an oral fluoropyrimidine prodrug with higher concentrations of fluorouracil attained in the tumor cells after enzymatic conversions. We conducted this … WebJun 23, 2014 · This is a multicenter, prospective, randomized, controlled phase III trial designed to assess the clinical performance of gemcitabine with cisplatin and observation vs. standard of care (observation alone in stage 1 and capecitabine and observation in stage 2) in patients after curative intent resection of BTC. Detailed Description:
Biliary Tract Cancers Treatment Regimens - Cancer Therapy Advisor
WebConclusions: Camrelizumab and apatinib combined with induction chemotherapy of NAB-paclitaxel, cisplatin and capecitabine and CCRT shows excellent distant metastatic control with acceptable safety, which is a new promising and effective systemic therapy regimen for high-risk of metastatic NPC patients. Clinical trial information: ChiCTR2000032317. WebIn this study, neoadjuvant chemotherapy with the triplet regimen of albumin-bound paclitaxel with cisplatin and capecitabine (APCC regimen) for locally advanced resectable ESCC showed high anti-tumor activities and significant effect on tumour downstaging. None of the evaluable patients (n=30) had disease progression after chemotherapy. birmingham city sky sports
Cisplatin and Capecitabine chemotherapy 363 - Velindre …
WebThis leaflet provides information on a course of chemotherapy called cisplatin and capecitabine. It will explain what this is and when and how it will be given. It will also tell you about common side effects that you may experience. Contact telephone numbers and details of how to obtain further information are given at the end of the leaflet. WebMar 1, 2013 · The patients were given docetaxel at 60 mg/m² on day 1, cisplatin at 20 mg/m² on days 1-3, and capecitabine at 1 250 mg/m² on days 1-14, and the treatment cycle was repeated ever 3 weeks. WebJan 19, 2024 · In the second-line setting, the ABC-06 trial of 162 patients with advanced biliary tract cancer demonstrated a significant, albeit modest, survival benefit for oxaliplatin-based combination therapy versus active symptom control alone after failure of an initial cisplatin/gemcitabine regimen (median 6.2 versus 5.3 months) [ 2 ]. birmingham city social services